Stoney they don't count when they drop 33% in the interim. You put out 5 of these per day, something will eventually hit. Granted you did assign the word "gummy" to it... but still, it dropped below $0.48 in the interim. A $68 dollar stock dropping to $48? >>>Same thing. People seem to lose that concept in penny stocks. Percentages are percentages. If Ollies dropped below $56, and you were in at $68, you'd say it was "closed".
Mersana to get $100M upfront fee from GSK for co-commercialization of XMT-2056 17:22 MRSN, GSK Mersana Therapeutics (MRSN) announced a global collaboration that provides GSK (GSK) an exclusive option to co-develop and commercialize XMT-2056, an Immunosynthen ADC that targets a novel epitope of HER2. XMT-2056 is designed to activate the innate immune system through STING signaling in both tumor-resident immune cells and in tumor cells."GSK brings highly complementary development and commercial capabilities, a wealth of immuno-oncology experience, a deep knowledge of the STING pathway and a shared vision for XMT-2056's broad potential," said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. "We believe this agreement solidifies Mersana's position as a partner of choice during this momentous period in the ADC space and serves as validation for our Immunosynthen platform, which takes ADCs beyond the cytotoxic realm by enabling a targeted stimulation of the innate immune system. Additionally, the agreement structure demonstrates our ability to generate meaningful non-dilutive capital upfront to support the development of our innovative candidates while also providing the potential for meaningful downstream economics." In preclinical models, XMT-2056 demonstrated robust anti-tumor activity as a monotherapy in both HER2-high and HER2-low expressing models, and enhanced efficacy has been shown when used in combination with multiple approved agents, including trastuzumab, pertuzumab, anti-PD-1, or trastuzumab deruxtecan. Preclinical data also suggest that XMT-2056 has the potential to enable immunological memory for prolonged anti-tumor activity. Mersana expects to initiate a Phase 1 clinical trial of XMT-2056 to investigate its potential in a range of HER2-expressing tumors such as breast, gastric and non-small-cell lung cancers. The U.S. Food and Drug Administration recently granted an orphan drug designation to XMT-2056 for the treatment of gastric cancer.Under the terms of the agreement, Mersana will receive an upfront option purchase fee of $100M. Mersana also is eligible to receive up to $1.36B in the form of an option exercise payment and development, regulatory and commercial milestone payments if GSK exercises its option. Show Related Items >>
Stock Of The Day -- Parr Pacific-- Description Par Pacific Holdings, Inc. owns and operates energy and infrastructure businesses. The company operates through three segments: Refining, Retail, and Logistics. The Refining segment owns and operates three refineries that produces ultra-low sulfur diesel, gasoline, jet fuel, marine fuel, distillate, asphalt, low sulfur fuel oil, and other associated refined products primarily for consumption in Hawaii, Pacific Northwest, Wyoming, and South Dakota. The Retail segment operates 119 fuel retail outlets, which sell merchandise, such as soft drinks, prepared foods, and other sundries in Hawaii under the Hele, 76, and nomnom brands; and gasoline, diesel, and retail merchandise in Washington and Idaho under the Cenex, nomnom, and Zip Trip brand names. The Logistics segment owns and operates terminals, pipelines, a single point mooring, and trucking operations to distribute refined products throughout the island of Oahu, Maui, Hawaii, Molokai, and Kauai. It also leases marine vessels; owns and operates a crude oil pipeline gathering system, a refined products pipeline, storage facilities, and loading racks in Wyoming; and a jet fuel storage facility and pipeline that serves Ellsworth Air Force Base in South Dakota. In addition, this segment owns and operates a marine terminal, a unit train-capable rail loading terminal, storage facilities, a truck rack, and a proprietary pipeline that serves Joint Base Lewis McChord. The company was formerly known as Par Petroleum Corporation and changed its name to Par Pacific Holdings, Inc. in October 2015. Par Pacific Holdings, Inc. was incorporated in 1984 and is headquartered in Houston, Texas. Par Pacific reports Q2 EPS $3.31, consensus $1.96 17:11 PARR Reports Q2 revenue $2.11B, consensus $1.83B. Reports adjusted EBITDA of $242.1M. We are pleased to report strong quarterly financial results due to rebounding demand, record market conditions and excellent operational reliability across our regions," said William Pate, President and Chief Executive Officer. "We remain focused on reducing debt and generating strong free cash flow." Par Pacific Holdings, Inc. (PARR) NYSE - NYSE Delayed Price. 16.69+0.31(+1.89%) At close: August 8 04:00PM EDT 18.65+1.96(+11.74%)<------------------ Pre-Market:07:38AM EDT
First Watch raises guidance on strong traffic trends Aug. 09, 2022 7:25 AM ETFirst Watch Restaurant Group, Inc. (FWRG) First Watch Restaurant Group (NASDAQ:FWRG) reported same-restaurant sales growth of 13.4% inQ2and same-restaurant traffic growth of 8.1%. Same-restaurant sales were up more than 30% compared to the level seen in 2019.
Siga Technologies announces BARDA exercise of procurement options 07:50 SIGA SIGA Technologies announced the exercise of procurement options under its 75A50118C00019 contract with the U.S. Department of Health and Human Services for the delivery to the U.S. government of intravenous formulation of TPOXX treatment courses valued at approximately $26M. These option exercises represent the first procurement option exercises for IV TPOXX under the 19C contract. Product deliveries of IV TPOXX in connection with these contract options are targeted for 2023. IV TPOXX is an important option for those who are unable to swallow. "These option exercises for the procurement of IV formulation of TPOXX as well as the funding of a post-marketing field study for IV TPOXX highlight the growing importance of a broad-based response to the substantial risks posed by the orthopox family of viruses, including smallpox and monkeypox," said Phil Gomez, CEO of SIGA. "The exercised options are among many procurement options under the 19C contract that remain to be exercised and, as such, we will continue to coordinate with the U.S. government toward future procurements of oral TPOXX and IV TPOXX." The procurement options, which were exercised by the Biomedical Advanced Research and Development Authority, part of the office of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, include the manufacture of bulk drug substance and the use of such substance to manufacture and deliver final drug product of IV TPOXX.